ARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.

ongoing

One of the main challenges in the domain of respiratory RNA delivery has been administration. Today, while 15 RNA therapeutics are undergoing clinical trials for pulmonary diseases, none has yet secured regulatory approval. Our nano-embedded microparticles (NEMs) represent a disruptive approach and paradigm shift in the field of RNA therapeutics for the treatment pulmonary diseases. Our IP-protected NEM technology comprises therapeutic RNA, which is encapsulated in lipid nanoparticles (LNPs) and formulated as an inhalable dry powder. This innovation builds the foundation to RNhale's two-pronged business concept: in-house drug development and RNA formulation in R&D partnerships. In brief, we have developed a standalone approach, pioneering an RNAi-based drug candidate for the treatment of moderate and severe allergic asthma. Additionally, our scalable, and indication independent production technology of RNA-loaded dry powders will be a second mainstay of our commercialization strategy.